Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 250 participants.

Also called NCT04687111

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Mark Ledwidge (from the registry)
Registry
  • NCT NCT04687111
  • EudraCT 2015-002928-53
Other papers using this trial's data
  • Cine-derived mitral annular relaxation velocity for detection of preclinical left ventricular diastolic dysfunction Magnetic resonance imaging, 2026-11 DOI, PubMed 42349572
  • Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial JAMA cardiology, 2023-04-01 DOI, PubMed 36884247, PMC9996460 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ireland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04687111. Randomized; quadruple masking; primary purpose prevention. Start 2015-12-16 (actual); primary completion 2021-06-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
Acronym
PARABLE
Condition
Atrial Remodeling
Condition
Myocardial Dysfunction
Condition
Left Ventricular Remodeling
Condition
Left Ventricular Diastolic Dysfunction
Condition
Hypertension
Condition
Cardiovascular Morbidity
Condition
Fibrosis Myocardial
Condition
Inflammatory Myopathy
Condition
Atrial Arrhythmia
Intervention (Drug)
Sacubitril-Valsartan
Intervention (Drug)
Valsartan
Lead sponsor
Mark Ledwidge (class: other)
Collaborator
The Heartbeat Trust (class: other)

Record details

Record id
cardio:ct-nct04687111
Content hash
fc78a278be92451690eec7183e645185349b4e9cb00f7a79a1ce42b150ebb7cb